StockNews.com Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

Stock analysts at StockNews.com assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other research firms have also recently issued reports on SRPT. BTIG Research boosted their target price on Sarepta Therapeutics from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, December 22nd. UBS Group raised Sarepta Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $100.00 to $158.00 in a research note on Friday, December 16th. Needham & Company LLC upped their price target on Sarepta Therapeutics from $160.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Cantor Fitzgerald upped their price target on Sarepta Therapeutics from $150.00 to $174.00 in a research note on Tuesday, December 13th. Finally, SVB Leerink reaffirmed an “outperform” rating and issued a $160.00 price target on shares of Sarepta Therapeutics in a research note on Friday, January 20th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Sarepta Therapeutics Trading Down 18.0 %

Shares of SRPT traded down $26.98 during mid-day trading on Thursday, hitting $122.69. 7,412,688 shares of the company’s stock traded hands, compared to its average volume of 1,428,116. The company has a quick ratio of 3.80, a current ratio of 4.13 and a debt-to-equity ratio of 4.01. Sarepta Therapeutics has a 1 year low of $61.28 and a 1 year high of $159.84. The firm has a market capitalization of $10.79 billion, a P/E ratio of -15.28 and a beta of 0.97. The business’s 50-day moving average price is $129.48 and its 200-day moving average price is $120.09.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last posted its earnings results on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.04. Sarepta Therapeutics had a negative return on equity of 117.29% and a negative net margin of 75.40%. The firm had revenue of $258.43 million for the quarter, compared to analysts’ expectations of $250.51 million. During the same period in the previous year, the firm earned ($1.42) earnings per share. The business’s revenue was up 28.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Sarepta Therapeutics will post -4.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FourThought Financial LLC raised its holdings in Sarepta Therapeutics by 43.5% in the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares during the last quarter. Hanseatic Management Services Inc. purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $35,000. Armstrong Advisory Group Inc. purchased a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $39,000. Cullen Frost Bankers Inc. purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $44,000. Finally, C M Bidwell & Associates Ltd. raised its holdings in shares of Sarepta Therapeutics by 1,966.7% during the second quarter. C M Bidwell & Associates Ltd. now owns 620 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares during the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.